Amedisys’ (AMED) Neutral Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald restated their neutral rating on shares of Amedisys (NASDAQ:AMED) in a report issued on Thursday morning, Benzinga reports. Cantor Fitzgerald currently has a $101.00 target price on the health services provider’s stock.

AMED has been the topic of a number of other research reports. StockNews.com raised Amedisys from a hold rating to a buy rating in a report on Saturday, May 4th. William Blair lowered Amedisys from an outperform rating to a market perform rating in a report on Monday, July 1st. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of Hold and a consensus target price of $100.67.

Amedisys Stock Performance

NASDAQ AMED opened at $98.25 on Thursday. The company has a quick ratio of 1.09, a current ratio of 1.09 and a debt-to-equity ratio of 0.31. Amedisys has a 52-week low of $89.55 and a 52-week high of $98.95. The business’s 50-day moving average price is $94.89 and its 200 day moving average price is $93.82. The firm has a market cap of $3.21 billion, a P/E ratio of -153.51, a P/E/G ratio of 2.38 and a beta of 0.79.

Institutional Investors Weigh In On Amedisys

A number of institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its position in shares of Amedisys by 0.4% during the 3rd quarter. Vanguard Group Inc. now owns 3,241,160 shares of the health services provider’s stock valued at $302,724,000 after acquiring an additional 12,137 shares during the period. Alpine Associates Management Inc. lifted its position in shares of Amedisys by 23.0% during the 4th quarter. Alpine Associates Management Inc. now owns 1,271,097 shares of the health services provider’s stock valued at $120,830,000 after acquiring an additional 237,600 shares during the period. Park West Asset Management LLC lifted its position in shares of Amedisys by 8.0% during the 4th quarter. Park West Asset Management LLC now owns 812,069 shares of the health services provider’s stock valued at $77,195,000 after acquiring an additional 60,350 shares during the period. Water Island Capital LLC lifted its position in shares of Amedisys by 185.0% during the 4th quarter. Water Island Capital LLC now owns 710,697 shares of the health services provider’s stock valued at $67,559,000 after acquiring an additional 461,368 shares during the period. Finally, Calamos Advisors LLC lifted its position in shares of Amedisys by 11.6% during the 2nd quarter. Calamos Advisors LLC now owns 397,347 shares of the health services provider’s stock valued at $36,476,000 after acquiring an additional 41,220 shares during the period. Hedge funds and other institutional investors own 94.36% of the company’s stock.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.